Chemotherapy for advanced ovarian cancer: overview of randomized trials.

@article{Thigpen2000ChemotherapyFA,
  title={Chemotherapy for advanced ovarian cancer: overview of randomized trials.},
  author={J. Tate Thigpen},
  journal={Seminars in oncology},
  year={2000},
  volume={27 3 Suppl 7},
  pages={11-6}
}
Until the mid-1970s, standard therapy for ovarian carcinoma was a single alkylating agent. Subsequently, combination chemotherapy was shown to be superior to such therapy. During the 1980s, cisplatin-based combination chemotherapy became the standard chemotherapy regimen for advanced ovarian cancer; however, other classes of agents with documented activity against ovarian tumors appeared to be cross-resistant with platinum. The introduction of paclitaxel (Taxol; Bristol-Myers Squibb Company… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
The series of randomized phase III studies that have compared the activity of platinum / paclitaxel with alternative regimens , including the previous standard combination of cisplatin / cyclophosphamide , support the combination of platinum / paclitaxel as the current standard chemotherapy for advanced ovarian cancer .
The series of randomized phase III studies that have compared the activity of platinum / paclitaxel with alternative regimens , including the previous standard combination of cisplatin / cyclophosphamide , support the combination of platinum / paclitaxel as the current standard chemotherapy for advanced ovarian cancer .
During the 1990s , the combination of platinum ( cisplatin or carboplatin ) plus paclitaxel rapidly evolved into front - line chemotherapy for advanced ovarian cancer .
During the 1990s , the combination of platinum ( cisplatin or carboplatin ) plus paclitaxel rapidly evolved into front - line chemotherapy for advanced ovarian cancer .
During the 1990s , the combination of platinum ( cisplatin or carboplatin ) plus paclitaxel rapidly evolved into front - line chemotherapy for advanced ovarian cancer .
During the 1990s , the combination of platinum ( cisplatin or carboplatin ) plus paclitaxel rapidly evolved into front - line chemotherapy for advanced ovarian cancer .
The series of randomized phase III studies that have compared the activity of platinum / paclitaxel with alternative regimens , including the previous standard combination of cisplatin / cyclophosphamide , support the combination of platinum / paclitaxel as the current standard chemotherapy for advanced ovarian cancer .
The series of randomized phase III studies that have compared the activity of platinum / paclitaxel with alternative regimens , including the previous standard combination of cisplatin / cyclophosphamide , support the combination of platinum / paclitaxel as the current standard chemotherapy for advanced ovarian cancer .
During the 1990s , the combination of platinum ( cisplatin or carboplatin ) plus paclitaxel rapidly evolved into front - line chemotherapy for advanced ovarian cancer .
The series of randomized phase III studies that have compared the activity of platinum / paclitaxel with alternative regimens , including the previous standard combination of cisplatin / cyclophosphamide , support the combination of platinum / paclitaxel as the current standard chemotherapy for advanced ovarian cancer .
The series of randomized phase III studies that have compared the activity of platinum / paclitaxel with alternative regimens , including the previous standard combination of cisplatin / cyclophosphamide , support the combination of platinum / paclitaxel as the current standard chemotherapy for advanced ovarian cancer .
The series of randomized phase III studies that have compared the activity of platinum / paclitaxel with alternative regimens , including the previous standard combination of cisplatin / cyclophosphamide , support the combination of platinum / paclitaxel as the current standard chemotherapy for advanced ovarian cancer .
The series of randomized phase III studies that have compared the activity of platinum / paclitaxel with alternative regimens , including the previous standard combination of cisplatin / cyclophosphamide , support the combination of platinum / paclitaxel as the current standard chemotherapy for advanced ovarian cancer .
The series of randomized phase III studies that have compared the activity of platinum / paclitaxel with alternative regimens , including the previous standard combination of cisplatin / cyclophosphamide , support the combination of platinum / paclitaxel as the current standard chemotherapy for advanced ovarian cancer .
The series of randomized phase III studies that have compared the activity of platinum / paclitaxel with alternative regimens , including the previous standard combination of cisplatin / cyclophosphamide , support the combination of platinum / paclitaxel as the current standard chemotherapy for advanced ovarian cancer .
The series of randomized phase III studies that have compared the activity of platinum / paclitaxel with alternative regimens , including the previous standard combination of cisplatin / cyclophosphamide , support the combination of platinum / paclitaxel as the current standard chemotherapy for advanced ovarian cancer .
During the 1980s , cisplatin - based combination chemotherapy became the standard chemotherapy regimen for advanced ovarian cancer ; however , other classes of agents with documented activity against ovarian tumors appeared to be cross - resistant with platinum .
The series of randomized phase III studies that have compared the activity of platinum / paclitaxel with alternative regimens , including the previous standard combination of cisplatin / cyclophosphamide , support the combination of platinum / paclitaxel as the current standard chemotherapy for advanced ovarian cancer .
During the 1990s , the combination of platinum ( cisplatin or carboplatin ) plus paclitaxel rapidly evolved into front - line chemotherapy for advanced ovarian cancer .
During the 1990s , the combination of platinum ( cisplatin or carboplatin ) plus paclitaxel rapidly evolved into front - line chemotherapy for advanced ovarian cancer .
ovarian neoplasmMay be treated byCisplatin
The series of randomized phase III studies that have compared the activity of platinum / paclitaxel with alternative regimens , including the previous standard combination of cisplatin / cyclophosphamide , support the combination of platinum / paclitaxel as the current standard chemotherapy for advanced ovarian cancer .
During the 1980s , cisplatin - based combination chemotherapy became the standard chemotherapy regimen for advanced ovarian cancer ; however , other classes of agents with documented activity against ovarian tumors appeared to be cross - resistant with platinum .
During the 1980s , cisplatin - based combination chemotherapy became the standard chemotherapy regimen for advanced ovarian cancer ; however , other classes of agents with documented activity against ovarian tumors appeared to be cross - resistant with platinum .
During the 1990s , the combination of platinum ( cisplatin or carboplatin ) plus paclitaxel rapidly evolved into front - line chemotherapy for advanced ovarian cancer .
The series of randomized phase III studies that have compared the activity of platinum / paclitaxel with alternative regimens , including the previous standard combination of cisplatin / cyclophosphamide , support the combination of platinum / paclitaxel as the current standard chemotherapy for advanced ovarian cancer .
During the 1990s , the combination of platinum ( cisplatin or carboplatin ) plus paclitaxel rapidly evolved into front - line chemotherapy for advanced ovarian cancer .
The series of randomized phase III studies that have compared the activity of platinum / paclitaxel with alternative regimens , including the previous standard combination of cisplatin / cyclophosphamide , support the combination of platinum / paclitaxel as the current standard chemotherapy for advanced ovarian cancer .
The series of randomized phase III studies that have compared the activity of platinum / paclitaxel with alternative regimens , including the previous standard combination of cisplatin / cyclophosphamide , support the combination of platinum / paclitaxel as the current standard chemotherapy for advanced ovarian cancer .
The introduction of paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) in the early 1990s , with its apparent lack of cross - resistance with platinum compounds , was a notable advance in ovarian cancer management that dramatically altered the standard of care .
The introduction of paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) in the early 1990s , with its apparent lack of cross - resistance with platinum compounds , was a notable advance in ovarian cancer management that dramatically altered the standard of care .
During the 1990s , the combination of platinum ( cisplatin or carboplatin ) plus paclitaxel rapidly evolved into front - line chemotherapy for advanced ovarian cancer .
All Topics